Wolf-
I don't care who makes the Wearables -contractors or in-house. (as long as they enter large scale production).
I believe the profit (royalties) for contracting out is not to exceed 10% (Amgen), whereas in-house it is in the order of 40% (similar to competitors).
Up till now (and still) UNIS is only a developer of injectable devises.
My hope is that in the upcoming AGM strategic partners will be announced.
I would assume that they would be Medimunme and Sanofi.
As shareholders we live in hope as there are few alternatives.
All IMO
UNS Price at posting:
5.6¢ Sentiment: Buy Disclosure: Held
